Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

Aaron Elliott, CEO of Ambry Genetics, discusses the company's approach to genetic testing and its unparalleled commitment to quality. What is Ambry Genetics’ approach to genetic testing?

today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.